New Zealand markets close in 6 hours 9 minutes

LLY Dec 2025 600.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
408.870.00 (0.00%)
As of 10:09AM EDT. Market open.
Full screen
Loading interactive chart…
  • Yahoo Finance Video

    Novo Nordisk, Eli Lilly fall on data from Roche's weight-loss pill

    Shares of Novo Nordisk (NVO) and Eli Lilly (LLY) are sliding after Roche (ROG.SW, RBO.PA) reported promising early-stage trial data from its weight-loss pill. Yahoo Finance Senior Reporter Anjalee Khemlani breaks down the trial results and how the medication may disrupt the current state of the weight-loss drug market as GLP-1 drugs like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro face record demand. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl

  • Investor's Business Daily

    Eli Lilly, Novo Nordisk — And Their Rivals — Skid On Roche's Weight-Loss Drug Results

    Eli Lilly and Novo Nordisk fell Wednesday after Roche released positive early-stage trial data on its oral weight-loss drug.

  • Zacks

    FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug

    The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.